Contract
Microbial Strain Development Associate
Posted on 6/19/2025
Sanofi
10,001+ employees
Develops pharmaceuticals and vaccines globally
No salary listed
Entry, Junior
Frankfurt, Germany
In Person
Canada Citizenship Required
- Practical experience in microbiology and microbial cultivation for expression performance cultivation using systems such as microtiter plates, shake flasks and microbioreactor systems (e.g. BioLector)
- Experience with DNA sequence design, cloning software (SnapGene, Benchling etc.) and modern molecular cloning techniques (Golden Gate, Gibson assembly, etc.), as well as with microbial expression systems
- Hands-on experience and expertise on molecular cloning, microbial strain engineering and analytical characterization of microbial strains
- Experience with NGS (Illumina, ONP, PacBio) and NGS-data analysis for validation of engineered expression strains
- Master’s Degree in molecular biology, microbiology, biochemistry or similar
- Fluent in English
- Work independently as a fully integrated member of a cross-functional, interdisciplinary, and international Chemistry, manufacturing and controls (CMC) development team
- Lead planning, design, execution of molecular biological experiments, strain engineering and process development
- Development, evaluation, and implementation of new methods or application and optimization of existing state-of-the-art process-relevant methods and molecular biological techniques
- Engineer and optimize microbial expression strains (E. coli, P. pastoris) for recombinant protein production
- Data analysis and data interpretation, presentation and reporting of results to international and interdisciplinary audience
- Follow, review, and share the latest project-related innovations and technology breakthroughs in academia and industry
- Contribute to collaborations with academic institutions and cross-company working groups focussing on recombinant protein production for biopharmaceutical application
- Share results through scientific publications, seminars, and webinars
- Good German and French skills would be a plus
- Experience with NGS (Illumina, ONP, PacBio) and NGS-data analysis for validation of engineered expression strains would be a plus
- Hands-on experience and expertise on molecular cloning, microbial strain engineering and analytical characterization of microbial strains would be a great plus
Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments worldwide. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline and adapt to different regulatory environments. The company's goal is to enhance health outcomes and improve the quality of life for people globally.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Simplify's Take
What believers are saying
- Sanofi's acquisition of Blueprint Medicines expands its rare immunological disease portfolio.
- The FDA approval of Dupixent addresses a large unmet need in dermatology.
- Sanofi's 20% profit growth in Q1 2025 highlights effective market strategies.
What critics are saying
- Increased competition in immunology could impact Sanofi's market share.
- Potential delays in regulatory approvals may affect new product launches.
- Integration challenges from acquisitions could disrupt operations and delay synergies.
What makes Sanofi unique
- Sanofi's R&D focuses on unmet needs in immunology, oncology, and rare diseases.
- The company leverages strategic partnerships to enhance its innovative treatment pipeline.
- Sanofi's global reach allows it to navigate diverse regulatory environments effectively.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
Adagene Inc. has secured a strategic investment of up to $25 million from Sanofi to advance its research and development, particularly for the clinical trials of muzastotug (ADG126), an anti-CTLA-4 SAFEbody targeting microsatellite stable colorectal cancer. This funding will extend Adagene's operational runway into 2027 and includes a phase 2 trial with over 100 patients. The partnership also allows Sanofi a role in Adagene's Scientific Advisory Board.
Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches: €750...
New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...
Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...